Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment

TACHIBANA, HIDEKAZU; INAKAWA, TORU; Nemoto, Yasuhiro; Ishihara, Hiroki; FUKUDA, HIRONORI; Yoshida, Kazuhiko; Iizuka, Junpei; HASHIMOTO, YASUNOBU; Tanabe, Kazunari; Kondo, Tsunenori; Takagi, Toshio

doi:10.21873/anticanres.15804

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SWOG, Sumanta et al [44], and SAVOIR trials were analyzed with the RoB2 tool, all of which are low-risk studies. For the observational studies, risk of bias assessment through ROBINS-I showed a low-risk in the Choueiri et al 2013 [38], Choueiri et al 2017 [39], and CALYPSO studies [46], and a moderate risk for the CREATE, Chanzá et al 2019 [42], and Tachibana et al 2022 [45] studies. The tables using RoB2 and ROBINS-I tools are available in Supplementary Tables S2 and S3.…”

Section: Quality Assessmentmentioning

confidence: 97%

Mesenchymal–Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis

Moraes,

Vilbert,

Alves

et al. 2023

IJMS

View full text Add to dashboard Cite

Papillary subtypes of renal-cell carcinoma (pRCC) represent 10–15% of the cases and commonly have MET alterations. This systematic review and single-arm meta-analysis evaluated MET inhibitor therapy (METi) efficacy and safety in adults with confirmed advanced pRCC. The search strategy included PubMed, Web-of-science, Cochrane, and Scopus. We used the DerSimonian/Laird random effect model for all analyses; p-value < 5% was considered significant, and heterogeneity was assessed with I2. Three clinical trials and six cohort studies were included with 504 patients; 31% were MET-driven. Our pooled analysis demonstrated an objective response rate (ORR) in MET-driven, MET-independent, and overall patients of: 36% (95%CI: 10–62), 0% (95%CI: 0–3), and 21% (95%CI: 1–41), respectively. One-year disease control and progression-free survival rates were, respectively, 70% (95%CI: 52–88) and 15% (95%CI: 10–20). Twelve- and twenty-four-month survival rates were, respectively, 43% (95%CI: 23–64) and 10% (95%CI: 0–30). The prevalence of adverse events of any grade and grades 3–5 were 96% (95%CI: 91–100) and 44% (95%CI: 37–50), respectively. We suggest METi has anti-tumor activity and is tolerable in patients with advanced pRCC.

show abstract

Section: Quality Assessmentmentioning

confidence: 97%

Mesenchymal–Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis

Moraes,

Vilbert,

Alves

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…By directing drugs against immune suppression and angiogenesis, two of the main survival mechanisms of RCC are engaged simultaneously (27). Clinical evidence also shows that TKI therapy initiated immediately after ICI treatment, in patient with poor response to immunotherapy, can be successful in stabilizing RCC progression (28,29). Further, TKI with multi-kinase activity, in particular those targeting the MAPK, can also suppress pathways driving the secretion of immunosuppressive cytokines.…”

Section: Resistance To Targeted and Immune Therapymentioning

confidence: 99%

The Potential Impact of New Drug and Therapeutic Modalities on Drug Resistance to Renal Cell Carcinoma

PINTO

2023

Anticancer Res

View full text Add to dashboard Cite

The treatment of advanced renal cell carcinoma has been substantially improved by the introduction of targeted and immune therapies and their respective combinations. Unleashing the activity of the immune system opened a new and successful front in the fight against cancers. Despite the benefits, drug resistance phenomena and adverse side effects can compromise efficacy. The development of new modalities of drugs and therapies with properties and mechanisms of action that break away from conventional medicines was expanded in recent years. This perspective discusses the prospects of these innovative and highly potent novel treatments in overcoming much of the current issues surrounding the resistance to approved renal cell carcinoma treatments and the challenges facing their introduction.

show abstract

Multiple drugs

2022

Reactions Weekly

View full text Add to dashboard Cite

Efficacy of Cabozantinib for Papillary Compared With Clear-cell Renal Cell Carcinoma Following Immune Checkpoint Inhibitor Treatment

Cited by 6 publications

References 0 publications

Mesenchymal–Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis

Mesenchymal–Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis

The Potential Impact of New Drug and Therapeutic Modalities on Drug Resistance to Renal Cell Carcinoma

Multiple drugs

Contact Info

Product

Resources

About